A COVID-19 vaccine that is being developed by American pharmaceutical corporation Pfizer, says its latest data suggests shots may be 90% effective at preventing the virus.
Pfizer Inc. says the study enrolled 43,538 volunteers, 42% of whom had diverse health backgrounds from the US and five other countries. The company says “no serious safety concerns” had been observed among the participants.
The positive preliminary data means the US company and its German partner, BioNTech, are on track to be the first to release the vaccine. In a press release on Monday morning, Pfizer says they estimate the ability to produce 1.3 billion doses — enough to vaccinate 650 million people — by the end of 2021.
- See also:
Roughly 50 million doses are expected to be available before the end of 2020.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
— Pfizer Inc. (@pfizer) November 9, 2020